4 results about "Propionic acid derivatives" patented technology

The invention relates to extended-release formulations comprising substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5'-monophosphate- activated protein kinase (AMPK). The invention further relates to methods of treating a condition comprising administering an extended-release formulation comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.

The invention relates to extended-release formulations comprising substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof that can activate adenosine 5′-monophosphate-activated protein kinase (AMPK). The invention further relates to methods of treating a condition comprising administering an extended-release formulation comprising AMPK-activating substituted indazole propionic acid derivatives, pharmaceutically acceptable salts, tautomers, or pharmaceutically acceptable salts of the tautomers thereof.

Provided herein are compounds and pharmaceutical compositions of formula I where R1, R2, R3, R4, R5 and R6 are as described herein. Also provided pharmaceutically acceptable salts or stereoisomers of these compounds. In addition methods are provided for inhibiting the binding of an integrin to treat various pathophysiological conditions.

The invention discloses a substituted pyridine propionic acid derivative and application thereof, and belongs to the field of chemical medicines. According to the pyridine propionic acid compound shown in the general formula (I) or the pharmaceutically acceptable salt of the pyridine propionic acid compound, in the compound, an A ring, a B ring and a C ring are independently selected from X1, X2, X3 and X4 are independently selected from N and CR, and at least one of X1, X2, X3 and X4 in the A ring is N. The compound disclosed by the invention has an excellent Lp (a) inhibiting effect and can be used as a medicine for reducing the Lp (a) level of plasma.